Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype

• Main Authors: Marika Comegna (Author), Vito Terlizzi (Author), Donatello Salvatore (Author), Carmela Colangelo (Author), Antonella Miriam Di Lullo (Author), Immacolata Zollo (Author), Giovanni Taccetti (Author), Giuseppe Castaldo (Author), Felice Amato (Author)
• Format: Book
• Published: MDPI AG, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The new CFTR modulator combination, elexacaftor/tezacaftor/ivacaftor (Trikafta) was approved by the FDA in October 2019 for treatment of Cystic Fibrosis in patients 6 years of age or older who have at least one F508del mutation in one allele and a minimal-function or another F508del mutation in the...